The present invention relates to various compositions comprising NAMPT and/or mutant thereof, processes for preparing these compositions, and various methods of using these compositions to prevent or treat an age-associated condition in a subject. The present invention also relates to methods of increasing NMN and/or NAD+ biosynthesis in a cell.

The invention concerns a pharmaceutical composition, kit or fixed-dose combination comprising a methionine depletion agent (MDA), and an anti-cancer immune modulator (ACIM), for use in the treatment of a disease or condition in a subject or patient in need of treatment thereof. Synergic combinations are provided. Cancer may be for example acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), pancreatic cancer, gastric cancer, colorectal cancer, prostate cancer, ovarian cancer, brain cancer, head and neck cancer or breast cancer.

Certain embodiments are directed to methods and compositions related to delivery of therapeutic agents via syncytiotrophoblast-derived extracellular vesicles (EVs).

Disclosed herein, inter alia, are nanoparticle compositions (e.g., silica nanoparticles) including insoluble drug nanocrystals and methods of using the same for treating cancer.

Provided herein are methods of using exosomes that function like minicells to deliver therapeutic agents to diseased or disordered cells. In particular, the exosomes can be targeted to particular areas of the body using growth factor gradients. These gradients also serve to trigger expression of proteins inside the exosomes, from transfected nucleic acids, at the desired target.

Methods and compositions involving exosomes or lipid nanovesicles are provided. For example, certain aspects relate to compositions comprising exosomes obtained from cells that have been induced to undergo oxidative stress or stimulated. Furthermore, some aspects of the invention provide methods of treating a subject at risk or having a demyelinating disorder using the compositions.

Compositions and provided to induce cells of the inner ear to renter the cell cycle and to proliferate. In particular, hair cells are induced to proliferate by administration of a composition which activates the Myc and Notch. Supporting cells are induced to transdifferentiate to hair cells by inhibition of Myc and Notch activity or the activation of Atoh1. Methods of treatment include the intracellular delivery of these molecules to a specific therapeutic target.

The present disclosure relates to isolated, therapeutic agent delivery platforms and, more particularly, to engineered, fusogenic particles and related methods for targeted delivery of therapeutic agents to cells. One aspect of the present disclosure relates to an isolated, fusogenic particle including a lipid envelope associated with at least one targeting protein, and a therapeutic agent contained within the fusogenic particle. The at least one targeting protein can be a viral fusion protein or a cognate receptor of a viral fusion protein. Other aspects of the present disclosure relate to in vivo and in vitro methods for delivering therapeutic agents to cells using the fusogenic particles.

The present invention relates treatments of a toxin in a subject. The toxin at least partially effects its toxicity in the subject via binding to a target cell of the subject. The present invention provides for methods, combinations and pharmaceutical compositions for decreasing or neutralizing the effect of a toxin in a subject, using, inter alia, an effective amount of a nanoparticle comprising an inner core comprising a non-cellular material, and an outer surface comprising a cellular membrane derived from a source cell. Exemplary toxins include acetylcholinesterase (AChE) inhibitors such as organophosphate poisoning.

The presently disclosed subject matter provides a biomimetic particle platform that can be used to simulate natural cells found throughout the body. The particle comprises a polymeric core of defined shape, size, and mechanical properties and a surface comprising naturally derived cell membranes, such as red blood cells or platelets. Together these features enable a level of biomimicry that can be appropriated for various drug delivery applications and cell engineering applications.